Sugi Predict

Sugi Predict / Compounds / SCHEMBL1992185

SCHEMBL1992185

SCHEMBL1992185

Fc1ccc2cc(Cl)nc(Cl)c2c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2A6 P11509 1/20 0.37
▸ KMT2A Q03164 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ BACE1 P56817 1/20 0.34
▸ S1PR2 O95136 1/20 0.34
▸ BCHE P06276 5/20 0.33
▸ ACHE P22303 5/20 0.33
▸ GRIN1 Q05586 5/20 0.33
▸ GRIN2A Q12879 5/20 0.33
▸ TYMS P04818 3/20 0.33
▸ AHR P35869 1/20 0.32
▸ DHODH Q02127 1/20 0.32
▸ CTDSP1 Q9GZU7 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29937094 1.00 MAPT (0.40) MAPTKDM4EALDH1A1MAPK1CYP1A2
SCHEMBL8167379 0.83 GRM4 (0.37) MAPTKDM4EALDH1A1MAPK1CYP1A2
SCHEMBL18455649 0.80 MAPT (0.41) MAPTKDM4EALDH1A1MAPK1CYP1A2
SCHEMBL11792799 0.78 CYP2A6 (0.39) ALDH1A1CYP2A6KMT2ABCHEACHE
SCHEMBL25362277 0.76 TRPA1 (0.42) MAPTKDM4EALDH1A1MAPK1CYP1A2
SCHEMBL30496101 0.76 TRPA1 (0.42) MAPTKDM4EALDH1A1MAPK1CYP1A2
SCHEMBL30676349 0.75 HTT (0.42) MAPTKDM4EALDH1A1CYP1A2CYP2A6
SCHEMBL14727433 0.75 KMT2A (0.44) MAPTKDM4EALDH1A1CYP1A2CYP2A6
SCHEMBL23887913 0.75 ESR1 (0.47) CYP1A2KMT2AMEN1
SCHEMBL17336482 0.75 TYMS (0.33) TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735453-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2026-05-06 — — EP disclosed
EP-4674841-A2 PHARMACEUTICAL COMPOUND Duke Street Bio Limited (GB) 2026-01-07 — — EP disclosed
WO-2025073554-A2 PARP1 INHIBITOR COMPOUNDS Duke Street Bio Limited (GB) 2025-04-10 — — WO disclosed
US-20250059208-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2025-02-20 — — US disclosed
WO-2025006704-A1 KRAS MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2025-01-02 — — WO disclosed
EP-4444305-A2 PHARMACEUTICAL COMPOUND Duke Street Bio Limited (GB) 2024-10-16 — — EP disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-07-18 — — US disclosed
WO-2024051763-A1 QUINAZOLINE HETEROCYCLIC DERIVATIVE OF KRAS MUTATION INHIBITOR FOR TREATING CANCER 深圳福沃药业有限公司 2024-03-14 — — WO disclosed
CN-117659050-A Quinazoline heterocyclic derivatives as KRAS mutation inhibitors for the treatment of cancer 深圳福沃药业有限公司 2024-03-08 — — CN disclosed
EP-2970202-B1 PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES TAKEDA PHARMACEUTICALS CO (JP) 2017-02-01 — — EP disclosed
US-20160310483-A1 PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES TAKEDA CALIFORNIA INC. 2016-10-27 — — US disclosed
US-9402841-B2 Pyridinyl and fused pyridinyl triazolone derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-02 — — US disclosed
EP-2970202-A1 PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES Takeda Pharmaceutical Company Limited (JP) 2016-01-20 — — EP disclosed
WO-2014164558-A1 PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-10-09 — — WO disclosed
US-20140256734-A1 PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-09-11 — — US disclosed
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 — — WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 — — US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 — — US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160310483-A1 PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES BTK, LCK, TYK2 MAPT 4472/4885KDM4E 1563/4885ALDH1A1 2160/4885
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO MAPT 3071/4885KDM4E 3351/4885ALDH1A1 297/4885
US-20240239788-A1 SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT KRAS, NRAS, HRAS MAPT 4552/4885KDM4E 3110/4885ALDH1A1 2871/4885
US-20140256734-A1 PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES BTK, LCK, TYK2 MAPT 4472/4885KDM4E 1563/4885ALDH1A1 2160/4885
US-20250059208-A1 KRAS MODULATING COMPOUNDS KRAS, NRAS, HRAS MAPT 3563/4885KDM4E 3464/4885ALDH1A1 4252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.